Explore breast cancer research in npj Breast Cancer, an open access journal with 6.5 Impact Factor and 7 days to first decision.
npj Breast Cancerhas now moved to a different platform and is no longer accepting new submissions on this system. If you wish to make a regular submission, please go to ournew manuscript tracking system. Existing or partial submissions
Please see the journal’s submission guidelines for detailed information, including how to format and submit Tables, Figures, and Supplementary Information. Article Articles should report substantial original primary research. Articles include received and accepted dates and are peer reviewed. Please not...
The MRE11–RAD50–NBS1 (MRN) complex is critical for genomic stability. Although germline mutations in MRN may increase breast cancer susceptibility, such mutations are extremely rare. Here, we have conducted a comprehensive clinicopathological study of
Analysis of urinary metabolites for breast cancer patients receiving chemotherapy by CE-MS coupled with on-line concentration. Clin. Biochem. 46, 1065–1073 (2013). Article CAS PubMed Google Scholar Alonso, A. et al. Urine metabolome profiling of immune-mediated inflammatory diseases. BMC Med....
npj Precision Oncologyhas a 2-year impact factor of 7.9 (2022), article downloads of 543,359 (2022) and 8 days from submission to first editorial decision (2022). Nature Portfolio Cancer Community Discover more about utilizing AI for precision oncology in a Behind the Paper post from Author...
Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer, and is associated with a poor prognosis due to frequent distant metastasis and lack of effective targeted therapies. Previously, we identified maternal embryonic leucine z
breast cancer (BRCA) and head and neck squamous cell carcinoma (HNSC) (Fig.8A, B). However, in clear cell renal cell carcinoma (KIRC), the expression of IFN-γ is unfavorable for patient prognosis (Fig.8C). In low-grade glioma (LGG), ovarian cancer (OV), and sarcoma (SARC), the...
The peroxisome proliferator-activated-β/δ (PPARβ/δ) was identified in 1994, but not until 1999 was PPARβ/δ suggested to be involved in carcinogenesis. Initially, it was hypothesized that expression of PPARβ/δ was increased during colon cancer pro
PD-L1 expression was higher in triple negative breast cancers. Neither B7-H4 nor PD-L1 were associated with survival in breast cancer. Our study shows there is a mutually exclusive pattern of B7-H4 with both tumor PD-L1 expression and TILs in all breast cancers, independent of breast cancer...